# Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer

> **NCT00494338** · PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Prostate Cancer

## Interventions

- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT00494338
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-11
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** due to celecoxib safety issues
- **Last updated:** 2009-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00494338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00494338, "Phase II Trial of Docetaxel and Celecoxib in Patients With Androgen Independent Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00494338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*